Division of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.
Cytosolic thioredoxin reductase (TrxR1) is an essential antioxidant selenoprotein oxidoreductase that carries out a wide range of reductive reactions in cells. A number of observations suggest that drug targeting of TrxR1 not only inhibits its normal function, but can also induce an oxidative NADPH oxidase activity in the otherwise inhibited enzyme. This, in turn, has a number of consequences. In normal cells, the main effect is typically a strong activation of the Nrf2 transcription factor, which up-regulates protective glutathione-dependent enzyme systems that, paradoxically, can protect such cells from further oxidative stress. Cancer cells, in contrast, typically do not survive upon drug targeting of TrxR1 and therefore several inhibitors of the enzyme display anticancer efficacy. Recent observations also suggest that TrxR1 targeting can modulate immune system functions. The latest developments in the field of TrxR1 targeting for therapy will be discussed.
Host: Arne Elofsson
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.